NCT01588418View on ClinicalTrials.gov

Acute Effect of Exenatide on Brain Glucose Metabolism

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Impaired Glucose Tolerance (IGT)Diabetes
Interventions
DRUG

Exenatide

Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study

DRUG

Placebo

Placebo was administered in random order 30 min before OGTT-PET study in the same subject

Trial Locations (1)

78229

Texas Diabetes Institute and UTHSCSA, San Antonio

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER